Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up

A. V. Balar, D. E. Castellano, P. Grivas, D. J. Vaughn, T. Powles, J. Vuky, Y. Fradet, J. L. Lee, L. Fong, N. J. Vogelzang, M. A. Climent, A. Necchi, D. P. Petrylak, E. R. Plimack, J. Z. Xu, K. Imai, B. H. Moreno, J. Bellmunt, R. de Wit, P. H. O'Donnell

Research output: Contribution to journal › Article › peer-review

23 Scopus citations

Fingerprint

Dive into the research topics of 'Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up'. Together they form a unique fingerprint.

Medicine & Life Sciences